Based on an update on the Food and medicine Administration's medicine shortage database on Wednesday, most dosages of Eli Lilly's extremely popular weight loss drug Zepbound and its diabetic equivalent Mounjaro will be in limited supply into the second quarter of this year due to a spike in demand.
Apart from the 2.5-milligram dosages of both medications, all other doses of Zepbound and Mounjaro are in low supply. A prior update said that certain dosages of both medications would only be available through April.
According to the most recent report, despite efforts by Eli Lilly and its primary competitor Novo Nordisk to boost manufacturing of those medicines, the market's insatiable demand for a popular class of diabetes and weight loss medications is still negatively affecting supply.
Finding injectable therapies is proving to be difficult for many people. which, over time, have become increasingly popular for aiding in their weight loss. These medications, which reduce appetite and control blood sugar by mimicking gut hormones, are frequently referred to as incretin medicines.
An inquiry on Eli Lilly's response to the FDA's statement on Wednesday was not immediately answered.
Eli Lilly declared in February that it had met its target of producing twice as many of these incretin medications by the end of 2023. According to the corporation, this year it will grow output with "equal urgency," with the biggest increases taking place in the second half of the year.
The business anticipates that by that time of year, its output of marketable dosages of incretin medications will have increased by at least 1.5 time the latter part of 2023.
Additionally, Eli Lilly has stated that incretin medication manufacture would begin at a new facility in Concord, North Carolina, by the end of the year, with medications ready for shipping in 2025. Over the next years, the corporation also plans to construct a few more sites, including two additional factories in Indiana and one in Germany.
Novo Nordisk has declared comparable initiatives. The FDA website reports that certain dosages of Novo Nordisk's diabetic medication Ozempic and weight loss medication Wegovy are also scarce.
Writing By Esmeralda Versewind
Head Editor & Chief : Kennedy Lucas Patterson
Presented By "Kennedy Lucas & Associates
© 2024 "Kennedy Lucas Patterson" Entertainment
© 2024 Kennedy Lucas & Associates
© 2024 The Vox Times By K.L.P Entertainment
© 2024 Kennedy Lucas Publishings LLC
© 2024 The Office Of Kennedy Lucas Patterson
Kommentare